CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) Director William Burke sold 18,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $26.64, for a total transaction of $479,520.00. Following the completion of the sale, the director directly owned 23,022 shares of the company’s stock, valued at $613,306.08. The trade was a 43.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
CeriBell Stock Down 0.8%
CBLL stock traded down $0.21 during trading on Friday, reaching $26.14. The stock had a trading volume of 267,634 shares, compared to its average volume of 372,668. The company has a quick ratio of 7.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.47 and a beta of 0.86. CeriBell, Inc. has a one year low of $12.40 and a one year high of $28.89. The company’s 50 day moving average is $25.49 and its two-hundred day moving average is $21.02.
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The firm had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. Equities research analysts forecast that CeriBell, Inc. will post -2.05 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on CBLL shares. TD Cowen increased their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. BTIG Research reissued a “buy” rating on shares of CeriBell in a research report on Wednesday, November 4th. Raymond James Financial restated a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. Finally, Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.
Read Our Latest Stock Analysis on CeriBell
Institutional Trading of CeriBell
Several hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new position in CeriBell in the second quarter valued at about $53,000. State of Wyoming bought a new position in shares of CeriBell during the 1st quarter valued at approximately $62,000. Quantbot Technologies LP purchased a new stake in shares of CeriBell during the 2nd quarter worth approximately $112,000. Principal Financial Group Inc. increased its stake in shares of CeriBell by 71.9% during the 1st quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock worth $425,000 after purchasing an additional 9,696 shares during the last quarter. Finally, Formula Growth Ltd. bought a new stake in shares of CeriBell in the 2nd quarter worth approximately $603,000.
CeriBell Company Profile
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
See Also
- Five stocks we like better than CeriBell
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
